Efficacy and safety of secukinumab in the treatment of moderate‐to‐severe plaque psoriasis: a randomized, double‐blind, placebo‐controlled phase II dose‐ranging study
Identifieur interne : 001007 ( Main/Exploration ); précédent : 001006; suivant : 001008Efficacy and safety of secukinumab in the treatment of moderate‐to‐severe plaque psoriasis: a randomized, double‐blind, placebo‐controlled phase II dose‐ranging study
Auteurs : K. A. Papp [Canada] ; R. G. Langley [Canada] ; B. Sigurgeirsson [Islande] ; M. Abe [Japon] ; D. R. Baker [États-Unis] ; P. Konno [Estonie] ; S. Haemmerle [Suisse] ; H. J. Thurston [Suisse] ; C. Papavassilis [Suisse] ; H. B. Richards [Suisse]Source :
- British Journal of Dermatology [ 0007-0963 ] ; 2013-02.
Abstract
Background Conventional systemic therapies for plaque psoriasis have not fully met the needs of patients, and although current biologic treatments are generally well tolerated, concerns exist with respect to long‐term safety. Interleukin (IL)‐17A is believed to be an important effector cytokine in the pathogenesis of psoriasis and is produced by Th17 cells, a class of helper T cells that act outside the established Th1/Th2 paradigm for regulation of innate and adaptive immunity.
Url:
DOI: 10.1111/bjd.12110
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001F01
- to stream Istex, to step Curation: 001F01
- to stream Istex, to step Checkpoint: 000125
- to stream Main, to step Merge: 001019
- to stream Main, to step Curation: 001007
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Efficacy and safety of secukinumab in the treatment of moderate‐to‐severe plaque psoriasis: a randomized, double‐blind, placebo‐controlled phase II dose‐ranging study</title><author><name sortKey="Papp, K A" sort="Papp, K A" uniqKey="Papp K" first="K. A." last="Papp">K. A. Papp</name></author><author><name sortKey="Langley, R G" sort="Langley, R G" uniqKey="Langley R" first="R. G." last="Langley">R. G. Langley</name></author><author><name sortKey="Sigurgeirsson, B" sort="Sigurgeirsson, B" uniqKey="Sigurgeirsson B" first="B." last="Sigurgeirsson">B. Sigurgeirsson</name></author><author><name sortKey="Abe, M" sort="Abe, M" uniqKey="Abe M" first="M." last="Abe">M. Abe</name></author><author><name sortKey="Baker, D R" sort="Baker, D R" uniqKey="Baker D" first="D. R." last="Baker">D. R. Baker</name></author><author><name sortKey="Konno, P" sort="Konno, P" uniqKey="Konno P" first="P." last="Konno">P. Konno</name></author><author><name sortKey="Haemmerle, S" sort="Haemmerle, S" uniqKey="Haemmerle S" first="S." last="Haemmerle">S. Haemmerle</name></author><author><name sortKey="Thurston, H J" sort="Thurston, H J" uniqKey="Thurston H" first="H. J." last="Thurston">H. J. Thurston</name></author><author><name sortKey="Papavassilis, C" sort="Papavassilis, C" uniqKey="Papavassilis C" first="C." last="Papavassilis">C. Papavassilis</name></author><author><name sortKey="Richards, H B" sort="Richards, H B" uniqKey="Richards H" first="H. B." last="Richards">H. B. Richards</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:527534383C1AD53B300D201147CAF2C69725FE52</idno><date when="2013" year="2013">2013</date><idno type="doi">10.1111/bjd.12110</idno><idno type="url">https://api-v5.istex.fr/document/527534383C1AD53B300D201147CAF2C69725FE52/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001F01</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001F01</idno><idno type="wicri:Area/Istex/Curation">001F01</idno><idno type="wicri:Area/Istex/Checkpoint">000125</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000125</idno><idno type="wicri:doubleKey">0007-0963:2013:Papp K:efficacy:and:safety</idno><idno type="wicri:Area/Main/Merge">001019</idno><idno type="wicri:Area/Main/Curation">001007</idno><idno type="wicri:Area/Main/Exploration">001007</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Efficacy and safety of secukinumab in the treatment of moderate‐to‐severe plaque psoriasis: a randomized, double‐blind, placebo‐controlled phase II dose‐ranging study</title><author><name sortKey="Papp, K A" sort="Papp, K A" uniqKey="Papp K" first="K. A." last="Papp">K. A. Papp</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Probity Medical Research, 135 Union Street East, Waterloo, ON N2J 1C4</wicri:regionArea><wicri:noRegion>ON N2J 1C4</wicri:noRegion></affiliation></author><author><name sortKey="Langley, R G" sort="Langley, R G" uniqKey="Langley R" first="R. G." last="Langley">R. G. Langley</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Dermatology, Dalhousie University, Halifax, NS</wicri:regionArea><wicri:noRegion>NS</wicri:noRegion></affiliation></author><author><name sortKey="Sigurgeirsson, B" sort="Sigurgeirsson, B" uniqKey="Sigurgeirsson B" first="B." last="Sigurgeirsson">B. Sigurgeirsson</name><affiliation wicri:level="1"><country xml:lang="fr">Islande</country><wicri:regionArea>Department of Dermatology, University of Iceland, Reykjavik</wicri:regionArea><wicri:noRegion>Reykjavik</wicri:noRegion></affiliation></author><author><name sortKey="Abe, M" sort="Abe, M" uniqKey="Abe M" first="M." last="Abe">M. Abe</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Dermatology, Gunma University Graduate School of Medicine, Maebashi</wicri:regionArea><wicri:noRegion>Maebashi</wicri:noRegion></affiliation></author><author><name sortKey="Baker, D R" sort="Baker, D R" uniqKey="Baker D" first="D. R." last="Baker">D. R. Baker</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Allergy, Asthma and Dermatology Research Center, Lake Oswego, OR</wicri:regionArea><placeName><region type="state">Oregon</region></placeName></affiliation></author><author><name sortKey="Konno, P" sort="Konno, P" uniqKey="Konno P" first="P." last="Konno">P. Konno</name><affiliation wicri:level="1"><country xml:lang="fr">Estonie</country><wicri:regionArea>Department of Dermatology, East Tallinn Central Hospital, Tallinn</wicri:regionArea><wicri:noRegion>Tallinn</wicri:noRegion></affiliation></author><author><name sortKey="Haemmerle, S" sort="Haemmerle, S" uniqKey="Haemmerle S" first="S." last="Haemmerle">S. Haemmerle</name><affiliation wicri:level="1"><country xml:lang="fr">Suisse</country><wicri:regionArea>Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Thurston, H J" sort="Thurston, H J" uniqKey="Thurston H" first="H. J." last="Thurston">H. J. Thurston</name><affiliation wicri:level="1"><country xml:lang="fr">Suisse</country><wicri:regionArea>Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Papavassilis, C" sort="Papavassilis, C" uniqKey="Papavassilis C" first="C." last="Papavassilis">C. Papavassilis</name><affiliation wicri:level="1"><country xml:lang="fr">Suisse</country><wicri:regionArea>Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Richards, H B" sort="Richards, H B" uniqKey="Richards H" first="H. B." last="Richards">H. B. Richards</name><affiliation wicri:level="1"><country xml:lang="fr">Suisse</country><wicri:regionArea>Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">British Journal of Dermatology</title><idno type="ISSN">0007-0963</idno><idno type="eISSN">1365-2133</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2013-02">2013-02</date><biblScope unit="volume">168</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="412">412</biblScope><biblScope unit="page" to="421">421</biblScope></imprint><idno type="ISSN">0007-0963</idno></series><idno type="istex">527534383C1AD53B300D201147CAF2C69725FE52</idno><idno type="DOI">10.1111/bjd.12110</idno><idno type="ArticleID">BJD12110</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0007-0963</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Background Conventional systemic therapies for plaque psoriasis have not fully met the needs of patients, and although current biologic treatments are generally well tolerated, concerns exist with respect to long‐term safety. Interleukin (IL)‐17A is believed to be an important effector cytokine in the pathogenesis of psoriasis and is produced by Th17 cells, a class of helper T cells that act outside the established Th1/Th2 paradigm for regulation of innate and adaptive immunity.</div></front></TEI><affiliations><list><country><li>Canada</li><li>Estonie</li><li>Islande</li><li>Japon</li><li>Suisse</li><li>États-Unis</li></country><region><li>Oregon</li></region></list><tree><country name="Canada"><noRegion><name sortKey="Papp, K A" sort="Papp, K A" uniqKey="Papp K" first="K. A." last="Papp">K. A. Papp</name></noRegion><name sortKey="Langley, R G" sort="Langley, R G" uniqKey="Langley R" first="R. G." last="Langley">R. G. Langley</name></country><country name="Islande"><noRegion><name sortKey="Sigurgeirsson, B" sort="Sigurgeirsson, B" uniqKey="Sigurgeirsson B" first="B." last="Sigurgeirsson">B. Sigurgeirsson</name></noRegion></country><country name="Japon"><noRegion><name sortKey="Abe, M" sort="Abe, M" uniqKey="Abe M" first="M." last="Abe">M. Abe</name></noRegion></country><country name="États-Unis"><region name="Oregon"><name sortKey="Baker, D R" sort="Baker, D R" uniqKey="Baker D" first="D. R." last="Baker">D. R. Baker</name></region></country><country name="Estonie"><noRegion><name sortKey="Konno, P" sort="Konno, P" uniqKey="Konno P" first="P." last="Konno">P. Konno</name></noRegion></country><country name="Suisse"><noRegion><name sortKey="Haemmerle, S" sort="Haemmerle, S" uniqKey="Haemmerle S" first="S." last="Haemmerle">S. Haemmerle</name></noRegion><name sortKey="Papavassilis, C" sort="Papavassilis, C" uniqKey="Papavassilis C" first="C." last="Papavassilis">C. Papavassilis</name><name sortKey="Richards, H B" sort="Richards, H B" uniqKey="Richards H" first="H. B." last="Richards">H. B. Richards</name><name sortKey="Thurston, H J" sort="Thurston, H J" uniqKey="Thurston H" first="H. J." last="Thurston">H. J. Thurston</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001007 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001007 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:527534383C1AD53B300D201147CAF2C69725FE52
|texte= Efficacy and safety of secukinumab in the treatment of moderate‐to‐severe plaque psoriasis: a randomized, double‐blind, placebo‐controlled phase II dose‐ranging study
}}
| This area was generated with Dilib version V0.6.29. |  |